Galectin-Binding Compounds with Metabolically Stable Spacers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic inflammatory diseases, fibrotic diseases, and cancer lack effective agents that can specifically target galectins, which are involved in inflammation, fibrosis, and cancer progression, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of compounds comprising pyranosyl and/or furanosyl structures conjugated through specific spacers like amide, sulfonamide, and phosphate linkages, which mimic glycoprotein interactions with galectins, enhancing binding specificity and affinity, and are metabolically stable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic inflammatory diseases, fibrotic diseases, and cancer, then general therapeutic effects are achieved, but specific targeting of galectins is lacking leading to inadequate therapeutic outcomes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (pyranosyl/furanosyl structures conjugated through amide, sulfonamide, or phosphate linkages) that target particular galectin proteins involved in inflammatory, fibrotic, and cancerous pathways. This localized molecular design enables selective binding to galectins rather than general anti-inflammatory or anti-cancer effects
Solution Approach 2:
The patent utilizes parameter changes by modifying chemical structures to alter binding affinity and specificity for galectins. The use of different spacer types (amide, sulfonamide, phosphate) and sugar structures (pyranosyl, furanosyl) creates compounds with varying molecular properties that optimize interaction with specific galectin targets, enhancing therapeutic reliability
2Reliability
If compounds with high binding affinity to galectins are designed, then therapeutic efficacy is improved, but metabolic stability may be compromised
Solution Approach 1:
The patent employs intermediary structures (amide, sulfonamide, phosphate linkages) that mediate between the sugar moiety and aromatic substitutions. These intermediary spacers provide metabolic stability while maintaining the compound's ability to bind galectins with high affinity, resolving the contradiction between efficacy and stability
Solution Approach 2:
The patent creates composite molecular structures combining pyranosyl/furanosyl sugar units with aromatic substitutions through stable linkage groups. This composite design integrates metabolically stable components (aromatic rings, stable linkages) with galectin-binding components (sugar structures), achieving both high affinity and metabolic stability
3Measurement precision
If aromatic substitutions are added to enhance interaction with amino acid residues in CRD, then binding specificity is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: a pyranosyl/furanosyl sugar unit for galectin recognition, a spacer region (amide, sulfonamide, or phosphate linkage) for structural stability, and aromatic substitution regions for enhanced binding specificity. This segmented design allows optimization of each component independently
4Duration of action of stationary object
If metabolically stable compounds are used, then duration of action is extended, but binding affinity may be reduced
Solution Approach 1:
The patent uses copying by creating synthetic analogs of natural galectin-binding sugars (pyranosyl and furanosyl structures) that replicate the natural binding interface while incorporating metabolically stable modifications. The aromatic substitutions copy and enhance the binding interactions of natural ligands while the stable linkage groups prevent metabolic degradation, achieving both extended duration and maintained affinity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively bind to galectins, such as Galectin-3, with high selectivity and affinity, offering therapeutic benefits in treating inflammatory, fibrotic, and cancerous conditions by modulating pathophysiological pathways.
Implementation Method 1
the compound is capable of mimicking glycoprotein interactions with lectins or galectin proteins which are known to modulate the pathophysiological pathways
Implementation Method 2
Such aromatic substitutions can enhance the interaction of the compound with amino acid residues (e.g. Arginine, Tryptophan, Histidine, Glutamic acid etc. . . . ) composing the carbohydrate-recognition-domains (CRD) of the lectins and thus strengthen the association and binding specificity
Data Source
AI summary
Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.